Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone626-305-5900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$40.60 million
Profitability
Miscellaneous
Employees156
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Xencor (NASDAQ:XNCR) Frequently Asked Questions
What is Xencor's stock symbol?
Xencor trades on the NASDAQ under the ticker symbol "XNCR."
How were Xencor's earnings last quarter?
Xencor Inc (NASDAQ:XNCR) released its quarterly earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.45) by $0.15. The biopharmaceutical company earned $19.49 million during the quarter, compared to analysts' expectations of $7.58 million. Xencor had a return on equity of 8.40% and a net margin of 28.46%. View Xencor's Earnings History.
When is Xencor's next earnings date?
What price target have analysts set for XNCR?
11 brokers have issued 1-year target prices for Xencor's stock. Their predictions range from $21.00 to $67.00. On average, they anticipate Xencor's share price to reach $46.2591 in the next year. This suggests a possible upside of 26.4% from the stock's current price. View Analyst Price Targets for Xencor.
What is the consensus analysts' recommendation for Xencor?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 1 sell rating, 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xencor.
What are Wall Street analysts saying about Xencor stock?
Here are some recent quotes from research analysts about Xencor stock:
- 1. Nomura analysts commented, "‘18087 (SSTR2xCD3) 2H19 to 1H20, 0 Est ASCO as Expected. SSTR2 is a validated target in NET and GIST, but these are solid tumors and suffer from tumor microenvironment effects and potential on-target toxicities. ‘18087 (SSTR2xCD3) is now the only bispecific in XNCR’s platform that we currently value. NVS to Our View. Recall, the clinical hold lifted in April; dosing to resume in coming weeks, but “tunable potency” still in question. Last update on clinicaltrials.gov was May 2 and included a Aug 2019 study completion date – we anticipate with appropriate study completion, NVS will return rights. More p 3. Checks – XNCRs’s Bispec C max -Dependent with Redesign." (8/8/2019)
- 2. According to Zacks Investment Research, "Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. " (7/20/2019)
- 3. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and 12-month price target of $40. Xencor reported 1Q 2019 earnings and offered a Business Update. No Ultromaris royalties were booked because they are booked ~1-2 quarters in arrears vs. Alexion. The company did have $112M in revenue from February’s Genentech deal, resulting in positive EPS for the quarter. Ultromaris and MOR208 revenues remain fast-approaching, near-term revenue opportunities. Alexion (ALXN: NC) reported $25M in Ultromaris sales in 1Q 2019. Xencor receives a low-single-digit royalty on these revenues; we model a 2% royalty." (5/12/2019)
Has Xencor been receiving favorable news coverage?
News articles about XNCR stock have been trending positive on Saturday, InfoTrie reports. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Xencor earned a news impact score of 2.5 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the next few days. View News Stories for Xencor.
Who are some of Xencor's key competitors?
Some companies that are related to Xencor include Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), SAGE Therapeutics (SAGE), Teva Pharmaceutical Industries (TEVA), Catalent (CTLT), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Beigene (BGNE), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND) and GW Pharmaceuticals PLC- (GWPH).
What other stocks do shareholders of Xencor own?
Who are Xencor's key executives?
Xencor's management team includes the folowing people:
- Dr. Bassil I. Dahiyat Ph.D., Co-Founder, CEO, Pres & Director (Age 49)
- Mr. John J. Kuch, Sr. VP of Fin., CFO & Sec. (Age 60)
- Dr. John R. Desjarlais, Sr. VP of Research & Chief Scientific Officer (Age 55)
- Dr. Paul A. Foster, Sr. VP & Chief Medical Officer (Age 65)
- Mr. Charles Liles, Associate Director and Head of Corp. Communications & Investor Relations
Who are Xencor's major shareholders?
Xencor's stock is owned by a number of of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (13.16%), Price T Rowe Associates Inc. MD (10.60%), Vanguard Group Inc. (7.79%), BlackRock Inc. (7.64%), EcoR1 Capital LLC (4.13%) and Northern Trust Corp (1.08%). Company insiders that own Xencor stock include Bassil I Dahiyat, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Institutional Ownership Trends for Xencor.
Which institutional investors are selling Xencor stock?
XNCR stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Artal Group S.A., Primecap Management Co. CA, Prudential Financial Inc., Victory Capital Management Inc., Cannell Peter B & Co. Inc., First Light Asset Management LLC and AQR Capital Management LLC. Company insiders that have sold Xencor company stock in the last year include John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Insider Buying and Selling for Xencor.
Which institutional investors are buying Xencor stock?
XNCR stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace LLP, EcoR1 Capital LLC, Nuveen Asset Management LLC, BlackRock Inc., Marshall Wace North America L.P., Panagora Asset Management Inc., Louisiana State Employees Retirement System and Renaissance Technologies LLC. View Insider Buying and Selling for Xencor.
How do I buy shares of Xencor?
Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Xencor's stock price today?
One share of XNCR stock can currently be purchased for approximately $36.60.
How big of a company is Xencor?
Xencor has a market capitalization of $2.07 billion and generates $40.60 million in revenue each year. The biopharmaceutical company earns $-70,410,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Xencor employs 156 workers across the globe.View Additional Information About Xencor.
What is Xencor's official website?
How can I contact Xencor?
Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected]
MarketBeat Community Rating for Xencor (NASDAQ XNCR)
MarketBeat's community ratings are surveys of what our community members think about Xencor and other stocks. Vote "Outperform" if you believe XNCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XNCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
